On September 12th, the U.S. Food and Drug Administration (FDA) website announced that they are providing guidance on the final rule regarding "Tobacco Products; Required Warnings for Cigarette Packages and Advertisements." The rule aims to promote greater public understanding of the negative health effects of smoking by adding new health warnings to cigarette packaging and advertisements.
The final rule was published in March 2020 and faced a challenge in the Eastern District Court of Texas. In December 2022, the district court overturned the rule. However, the government appealed this decision, and in May 2024, the United States Fifth Circuit Court of Appeals overturned the district court's ruling, reinstating the final rule, which is now officially in effect. The plaintiffs are now waiting for review by the Supreme Court.
In the newly released guidance document, the FDA plans to exercise enforcement discretion for 15 months or until December 12, 2025, generally not enforcing the requirements of final rules. For products manufactured before December 12, 2025, the FDA will also provide an additional 30-day grace period, or until January 12, 2026. The FDA has chosen a 15-month orderly transition period, consistent with the initially envisioned 15-month compliance period of the Family Smoking Prevention and Tobacco Control Act, but impacted by litigation proceedings.
The final rule also requires the industry to submit plans and obtain FDA approval to ensure that warning labels on cigarette packaging are displayed and distributed randomly and evenly, while rotating warning labels on cigarette advertisements quarterly. Therefore, entities with cigarette health warning plans that have not yet been approved are advised to submit such plans as soon as possible, but must do so within five months or by February 10, 2025. Entities that had previously submitted cigarette plans to the FDA do not need to resubmit their plans unless they wish to make changes.
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com
